Last reviewed · How we verify
Clofarabine, Cyclophosphamide
At a glance
| Generic name | Clofarabine, Cyclophosphamide |
|---|---|
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (PHASE2)
- Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (PHASE2)
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (PHASE2, PHASE3)
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (PHASE3)
- Personalized NK Cell Therapy in CBT (PHASE2)
- CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (PHASE1)
- TAC T-cells for the Treatment of HER2-positive Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |